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Background:Multiple sclerosis (MS) is a heterogeneous disorderwith a progressive course that is difﬁcult to predict
on a case-by-case basis. Natural history studies of MS have demonstrated that age inﬂuences clinical progression
independent of disease duration.
Objective: To determine whether age would be associated with greater CNS injury as detected by magnetization
transfer MRI.
Materials and methods: Forty MS patients were recruited from out-patient clinics into two groups stratiﬁed by age
but with similar clinical disease duration as well as thirteen controls age-matched to the older MS group. Images
were segmented by automated programs and blinded readers into normal appearing white matter (NAWM),
normal appearing gray matter (NAGM), and white matter lesions (WMLs) and gray matter lesions (GMLs) in the
MS groups. WML and GML were delineated on T2-weighted 3D ﬂuid-attenuated inversion recovery (FLAIR) and
T1 weighted MRI volumes. Mean magnetization transfer ratio (MTR), region volume, as well as MTR histogram
skew and kurtosis were calculated for each region.
Results: All MTR measures in NAGM and MTR histogram metrics in NAWM differed between MS subjects and
controls, as expected and previously reported by several studies, but not betweenMS groups. However, MTRmea-
sures in the WML did signiﬁcantly differ between the MS groups, in spite of no signiﬁcant differences in lesion
counts and volumes.
Conclusions:Despitematching for clinical disease duration and recording no signiﬁcantWML volume difference,we
demonstrated strong MTR differences in WMLs between younger and older MS patients. These data suggest that
aging-related processesmodify the tissue response to inﬂammatory injury and its clinical outcome correlates inMS.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
Multiple sclerosis (MS) is a clinically heterogeneous disease most
commonly presenting in young adults with a relapsing–remitting
(RRMS) course. For the majority, the course of disease eventually
becomes progressively disabling (secondary progressive, SPMS).WM, normal appearing white
hite matter; GM, gray matter;
ng Sciences, Burlington Danes
UK. Tel.: +44 208 008 6264;
D. Newbould).
work.
. This is an open access article underNatural history studies have demonstrated that age affects disease
progression independent of disease duration (Koch et al., 2007;
Scalfari et al., 2011). Latency to development of SPMS is reduced in
older patients, with age of onset representing an independent predictor
for time to progression (Koch et al., 2007). Indeed, the effects of age on
progressive disability occur despite variation in the initial disease
pattern preceding SPMS (Confavreux and Vukusic, 2006). Aging-
associated delay in remyelination may underlie this phenomenon.
Complete remyelination of gliotoxin-induced demyelination occurs
faster in younger rats when compared with older rats (Shields et al.,
1999) and by pairing their circulatory systems, it was demonstrated
that exposure of older mice to the circulatory systems of younger
mice led to a restoration of youthful remyelinatory potential (Ruckh
Julia et al., 2012).the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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clinical practice in MS (McDonald et al., 2001; Polman et al., 2011)
parameters derived from conventional MRI have limited correlations
with clinical measures of disability (Filippi et al., 1995a). While MRI is
sensitive in identifying focal white matter MS lesions, conventional
T1- and T2-weightedMRprotocols cannot readily detect subtle changes
in normal appearing white matter (NAWM) (Filippi and Agosta, 2007)
nor cortical gray matter lesions, which have been demonstrated at
post-mortem (Evangelou et al., 2000). Magnetization transfer (MT)
parameters have been used to detect and quantify changes occurring
outside lesions identiﬁed on conventional MRI. MT contrast represents
proton interactions between free ﬂuid and macromolecules, such as
myelin (Filippi and Agosta, 2007) and provides a potential in vivo bio-
marker of ultrastructural integrity which is sensitive to pathology
in vivo in a variety of neurological diseases, including MS. The most
widely examined MT contrast parameter is the magnetization transfer
ratio (MTR), representing the percentage reduction of MR signal when
applying off-resonance radiofrequency irradiation. Reduced MTR sug-
gests reduced exchange between macromolecular-associated and free
water, most likely due to a reduction in the size of the macromolecular
pool.
Mean MTR signals in NAWM are lower in MS patients, compared
with controls (Filippi et al., 1995b), and MTR in the GM has been
shown to predict disability progression (Agosta et al., 2006). The precise
nature of tissue damage associated with MTR abnormalities is under
contention; some studies have demonstrated strong correlations be-
tween myelin content and MTR (Schmierer et al., 2004), while others
have demonstrated correlations between MTR and axonal density in
both lesions and NAWM (van Waesberghe et al., 1999).
Here, in order to investigate the biological substrates underlying the
clinical effects of age in MS, we examined to what extent CNS tissue
injury differs amongst older and younger MS patients. We therefore
selected two groups ofMS patients differing by age but not by the dura-
tion of their disease and one healthy control cohort age-matched to the
older MS patients to account for and interpret any age-related differ-
ences from normal aging. We examined the MTR distribution in visible
white matter lesions and normal appearing gray and white matter.
2. Materials and methods
2.1. Patients
Forty patients with rapidly evolving MS enrolled in the Medical
Research Council-funded Patient Research Cohort Rapidly Evolving
Multiple Sclerosis study (PRC-REMS [http://clinicaltrials.gov/ct2/show/
NCT01044576]) and thirteen healthy controls enrolled in GSK-
sponsored EMI115241 were selected for inclusion. The studies had
ethical approval from the London — Chelsea NRES Committee (NHS
REC Ref. 09/H0708/61) and Essex 1 Research Ethics Committee (Ref:
11/EE/0026), respectively, and all subjects gave full informed consent
in writing. All MS patients included had a diagnosis of MS according to
the revised McDonald's criteria (Polman et al., 2011) with RRMS or
SPMS, disease duration ≤5 years from clinical diagnosis, EDSS score
2.0–6.0 at screening and meeting criteria for highly active and/or
treatment-refractory MS activity deﬁned as: (a) Two or more clinical
exacerbations in the previous 12 months, regardless of treatment;
OR: (b) one clinical exacerbation and sustained increase in EDSS of
at least 1 point in the previous 12 months after receiving, declining
or not tolerating immune-modifying treatment, OR: (c) evidence of
gadolinium (contrast)-enhancement or increase of T2 lesion load at
MRI after receiving, declining or not tolerating immune-modifying
treatment. Patients were assigned to one of two cohorts depending
on their age: ‘young MS’ aged 25–35 years [n = 20] or ‘older MS’
45–60 years [n = 20], both ranges inclusive. Healthy control subjects
were included in the ‘older control’ cohort to age-match the ‘older MS’
group. Cohort demographics common for all three groups are reportedin Table 1.MS-relevant characteristics for the twoMS groups are report-
ed in Table 2. At the blinded MRI data quality check, two patients from
the ‘older MS’ group had excessivemovement artifacts and two healthy
control subjects had incidental ﬁndings. These four subjects were
excluded from their respective groups prior to analysis.
2.2. MRI acquisition
MRI images were acquired on a 3 Tesla Magnetom Verio scanner
(Siemens Healthcare, Erlangen, Germany) at software version VB17
using a 12-channel phased array head coil with an 8-channel phased
array neck coil. The following sequences were obtained in a single
imaging session at a single site (Fig. 1).
Pre- and post-contrast T1-weighted 3D MPRAGE volumes were
acquired based on the ADNI-GO recommended parameters (Jack et al.,
2008): 256 × 192 mm ﬁeld of view (FOV), 1 mm3 isotropic resolution,
parallel imaging (PI) factor of 2, in 5 m: 21 s. Gadolinium injection
(Gadoterate meglumine, Dotarem, Guerbet, 0.1 mmol/kg) was given
b5 min prior to the acquisition of the post-contrast volume.
A T2-weighted ﬂuid-attenuated inversion recovery (FLAIR) 3D
volume with 1 mm3 isotropic resolution for the delineation of white
matter lesions was acquired, using a 3D T2w variable-refocusing angle
TSE readout (Mugler and Brookeman, 2003). 160 sagittal sections in a
single 3D slab were acquired with the following parameters: echo
time (TE) 395 ms, repetition time (TR) 5 s, inversion time (TI)
1800 ms, 250 × 250 mm FOV, and a PI factor of 2 in 5 m: 52 s.
Magnetization transfer (MT) images were acquired using two
pseudo proton density weighted (PDw) 3D spoiled gradient echo
acquisitions (fast low angle shot (FLASH)). Common parameters
include: 256 × 240 mm FOV, 192 sagittal sections per 3D slab,
1 mm3 isotropic resolution, parallel imaging factor of 2, TR of 27 ms
with a ﬂip angle of 5° in 7 m: 20 s, and 6 echoes acquired using
630 Hz/pixel bandwidth with TEs every 1.95 ms from 1.95 to
11.7 ms. Each high-bandwidth echo was summed to increase SNR
without introducing off-resonance effects of low readout bandwidth
(Helms and Dechent, 2009). One of these PDw volumes used an off-
resonanceMTpulse to addMTweighting (MTw), with a 12.24ms dura-
tion Gaussian pulse at 2.2 kHz off resonancewith a nominal ﬂip angle of
540°.
All volumes were co-registered using the FSL Linear Image Registra-
tion Tool (FLIRT) (Jenkinson et al., 2002) to the MPRAGE volume to
account for any movement between the acquisitions. MTR maps were
calculated using the MTw and PDw acquisitions by the equation:
MTR ¼ 100  SPDw−SMTwð Þ=SPDw: ð1Þ
2.3. MRI segmentation
Lesion segmentation in the MS cohorts was performed by a semi-
automated thresholding techniquewithmanual correction (JimVersion
6.0, http://www.xinapse.com/software.html) performed by a trained
observer and corroborated by a second experienced observer, both
blinded to age and clinical status. Areas were segmented from T1-
weighted MPRAGE and T2-weighted FLAIR images to produce regions
of interest (ROIs) representing white (WML) and gray matter lesions
(GML). The FLAIR was used in conjunction with the MPRAGE due
to advantages with respect to lesion conspicuity and detectability
(Rydberg et al., 1994; Filippi et al., 1996).
Brain extraction and white/gray matter segmentation in all three
groups was performed on T1-weighted images by an automated tech-
nique based on prior probabilities (Smith et al., 2002), subtracting the
lesion masks from the tissue classiﬁcations in the MS groups to give
normal appearing gray matter (NAGM) and white matter (NAWM).
Segmentation masks were visually inspected by a trained observer,
blinded to group, for assessment of the quality of segmentation.
Table 1
Demographics of study population.
‘Older control’ ‘Young MS’ ‘Older MS’ P
(oC/yMS)
P
(oC/oMS)
P
(yMS/oMS)
Age (years) 48.5 (9.0) 30.4 (3.3) 49.7 (4.1) b0.001 0.30 b0.001
Age range (years) 37–65 25–36 44–57
Sex (f/m) 8/3 17/3 13/5 0.63 1.0 0.44
MS subtype 20 RRMS 16 RRMS; 2 SPMS 0.42
Disease duration (mean yrs ± SD) 2.2 ± 1.5 2.2 ± 1.2 0.59
EDSS (median, range) 2.5 (2–6) 3.75 (2–6) 0.019
Prior year clinical relapses (mean ± SD) 2.0 ± 0.7 1.7 ± 0.7 0.19
Disease modifying treatment
(n treated patients)
At any time
9
(3 Avonex, 2 Betaferon,
3 Copaxone, 1 Rebif)
12
(3 Avonex, 2 Betaferon,
3 Copaxone, 3 Rebif,
1 azathioprine)
On-going at time of scan 8
(2 Avonex, 2 Betaferon,
3 Copaxone, 1 Tysabri)
7
(1 Avonex, 2 Betaferon,
2 Copaxone, 2 Tysabri)
All values are reportedwith the standarddeviation inparentheses. Legend:Older controls vs. youngMS (oC/yMS), older controls vs. olderMS (oC/aMS), youngMS vs. olderMS (yMS/oMS).
Bold typeface indicates a P value less than 0.05.
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Due to the small volume of the GML ROI, with a mean size of
96 mm3, and the low sensitivity of FLAIR to detect GMLs which may
be a factor in theﬁndingof GMLs in only 12of 20 subjects in the younger
MS group and 9 of 18 subjects in the older MS group, the GML ROI was
excluded from further analysis. Each of the remaining three segmented
tissue type masks were applied to the MTR maps to give both the ROI-
based measure of mean MTR as well as to generate histograms of the
MTR distribution in each ROI using 1 percent unit (p.u.) wide bins
(van Buchem et al., 1996). Each histogram was normalized by dividing
by the number of pixels in each histogram, to remove the inﬂuence of
variation of brain and lesion volumes between subjects. For each distri-
bution, the skew and kurtosis of the single modal distribution were cal-
culated. Finally, the volume of each ROI was recorded.
Differences in MTR and ROI metrics and in demographic and clinical
variables at the group level were assessed using theWilcoxon rank sum
test, except the gender, which used Fisher's exact test. Spearman's rank
correlation coefﬁcient was used to investigate associations between
histogram metrics and functional status (EDSS scores) and the Pearson
correlation coefﬁcient for correlations between MTR metrics and brain
volumes and log transformed lesion volumes.Multivariate logistic anal-
ysis was employed with MT variables input as individual predictors of
age to distinguish which variables are independently correlated with
the age group. The ability of the combination of the variables includedTable 2
MTR measures between groups.
ROI Older control ‘Young MS’
Mean (p.u.) NAWM 48.30 (0.87) 48.32 (1.26)
NAGM 41.27 (0.74) 40.16 (1.19)
WML – 40.54 (1.94)
Skew NAWM −0.873 (0.132) −1.213 (0.338)
NAGM −0.820 (0.124) −1.122 (0.187)
WML – −0.839 (0.361)
Kurtosis NAWM 5.421 (0.534) 8.689 (2.757)
NAGM 4.747 (0.394) 5.577 (0.775)
WML – 4.392 (1.396)
Volume (cc.) NAWM 604.16 (72.71) 525.87 (52.23)
NAGM 572.5 (52.23) 559.10 (46.28)
WML – 10.57 (11.34)
All values are reported with the standard deviation in parentheses. Legend: Older controls vs. you
Bold typeface indicates a P value less than 0.05.in the multivariate model to distinguish younger and older patients
was assessed by a ROC analysis and quantiﬁed by the area under the
curve (AUC). A two-tailed p-value of b0.05 was considered signiﬁcant.
3. Results
3.1. Older patients have higher disability independent of other
clinical variables
Themean age at the time ofMRI scanwas 30.4± 3.3 years (mean±
SD) in the youngerMS group, 49.7±4.1 in the olderMS group, and 48.0
± 9.8 years in the older control group. The ages in the two older groups
did not signiﬁcantly differ, but were strongly different to the young
group (Fig. 2a). Gender distribution was similar in all groups
(Table 1). Though groups did not signiﬁcantly differ for clinical disease
duration (p= 0.59; Fig. 2b), recent relapses (p= 0.19; Fig. 2c) and pre-
vious or ongoing disease-modifying treatments, EDSS was signiﬁcantly
higher in the older group (younger group EDSS 2.5 (range 2–6), older
group EDSS 3.8 (range 2–6); p= 0.019; Fig. 2d).
3.2. MTR measures
As seen in the rightmost column of Table 2, all the MTR measures
were similar in the NAGM and NAWM in both MS groups. This stands
in contrast to each MTR metric in the WML, which was signiﬁcantly‘Older MS’ P
(oC/yMS)
P
(oC/oMS)
P
(yMS/oMS)
48.01 (1.26) 0.964 0.505 0.452
39.84 (1.25) 0.009 0.002 0.424
38.26 (2.16) – – 0.0025
−1.277 (0.344) 0.0035 0.00095 0.563
−1.216 (0.139) b0.00001 b0.00001 0.089
−0.570 (0.306) – – 0.026
8.826 (2.362) 0.00058 b0.00001 0.87
5.524 (0.819) 0.0025 0.0068 0.83
3.241 (0.797) – – 0.0074
524.70 (62.28) 0.00097 0.0042 0.947
522.63 (62.28) 0.55 0.037 0.082
6.54 (6.65) – – 0.196
ng MS (oC/yMS), older controls vs. older MS (oC/aMS), young MS vs. older MS (yMS/oMS).
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signiﬁcantly lower in the older group (38.26 ± 2.16 p.u) versus the
younger group (40.54 ± 1.94 p.u.) even though the number of white
matter lesions and total WML volumes did not differ signiﬁcantly. The
median white matter lesion volume was greater in the younger group,
but this did not reach signiﬁcance as both groups had a large variability
in the number and size of white matter lesions. The MTR distribution in
WML can be seen in Fig. 3c to contain a higher proportion of low MTR
voxels in the older MS group, thus altering the skew and kurtosis of
these distributions.
Mean MTR was not different between controls and either MS group
in NAWM,which excluded anyMR-visible lesions. However, meanMTR
was signiﬁcantly different between controls and both MS groups in the
NAGM. In both the NAWMand NAGM, the skew and kurtosis measures
were signiﬁcantly different from controls.
3.3. MTR parameters and disability can discriminate older and younger
patient groups
A multivariate logistic regression including the MTR parameters
signiﬁcantly different between age groups (mean MTR, skew, and
kurtosis in WML) was run, adjusting for EDSS, brain volume, T2 and
T1 lesion volumes. The ﬁnal model (selected with a forward selection
procedure) included EDSS (OR= 4.01, p= 0.011), graymatter volume
(OR = 0.95, p = 0.001), T1 lesion volume (log scale) (OR = 0.10, p =
0.001) and mean lesion MTR (OR = 0.93, p = 0.03) as independent
predictors of age group. This observation indicates that mean MTR in
WML is signiﬁcantly different between the two age groups also
adjusting for other variables associated with age and disease (EDSS,
brain and T1 lesion volumes). The area under the ROC curve (Fig. 4)
derived from these 4 parameters' combination was 0.95 (95% CI
= 0.88–1.00), indicating that this set of variables is effective at dis-
criminating younger and older patients.
4. Discussion
In this study, brain MTR was compared between three groups: two
MS groups differing only by age, and a control group that was age-
matched to the older MS group. The MS cohort studied had a high
disease activity. This cohort was chosen to allow a more robust investi-
gation of lesion tissue as a larger number and/or volume of lesions was
expected as compared to a less active or inactive group of patients.
Further, any age-related differences in the degree of normal or lesional
tissue injury would be more clinically relevant in such a population.
After excluding abnormal tissue, the MTR distribution in NAWM and
all MTR metrics in NAGM were found to be strongly different between
controls and both MS groups, a similar result to many previous studies
(Filippi and Agosta, 2007). Our study also showed similar MTR results
in NAGM and NAWM in both the young and older MS groups, with no
age-related effect. In strong contrast, MTR was signiﬁcantly lower in
WML tissue in the older MS group when compared with the young.
There have been several previous studies relating age toMTR in both
MS and healthy populations. Rovaris et al. (2003) usedwhole-brain his-
tograms to determine the average MTR, peak height, and peak position
in a control population of 89 subjects with a mean age of 43.6 years
(range 11–76). After excluding T2 hyperintensities, which correlated
well with age, no age-related trends were found in any MTR measure.
Mehta et al. (1995) used an ROI-based approach, and also saw no age
effects in gray matter (GM) or white matter (WM) ROIs in 68 healthy
subjects with an age range of 21 to 78. This contrasts with the healthy
subject studies (51 subjects, mean age 55 years, range 21–77) of
Hofman et al. (1999), who found an age-related decline in mean MTR
in the WM, and Ge et al. (2002) (52 subjects, mean age 46 years,
range 20–86), who found an age-related decline in several MTR histo-
gram metrics in the WM and GM. However, neither study excluded
abnormal areas deﬁned on conventional MR images. Benedetti et al.(2006) reanalyzed the healthy subject data of Rovaris et al. (2003),
splitting histograms into gray and white matter, and found signiﬁcant
correlations between age and MTR histogram parameters only for the
GM, not for the NAWM. WM T2 hyperintensities were masked out
before creating the MTR histograms for NAWM. After correcting for
the number of T2 hyperintensities, gender, and tissue volume, no MTR
measure remained signiﬁcantly correlated with age. Silver et al.
(1997) found small but statistically signiﬁcant age-related declines in
MTR in several WM ROIs in 41 healthy subjects (mean age 35.5 years,
range 16–55) which excluded T2 hyperintensities.
In an MTR study of 30 primary progressive MS patients (mean age
40.7 years, range 25–51) and 30 healthy controls (mean age
39.4 years, range 27–53), Dehmeshki et al. (2003) found no correlation
between age andMTR in any of themetrics in NAWM nor NAGM in MS
patients, though themean NAGMMTRwas negatively correlated to age
in controls. Finally, in anMTR study comparing 22 age-matched controls
with 22 RRMS subjects with disease onset either before age 18 (mean
age at scan 21.3, range 15–29) or after age 18 (mean age at scan
37.6 years, range 25–48), Oguz et al. (2010) found reduced MTR in
the NAWM when compared to controls, but no age-related effect
between the two MS groups.
Several conclusions can be drawn from this body of previous work.
First, it is important to delineate visibly abnormal areas from normal
appearing parenchyma when considering MTR metrics; the majority
of studies that excluded visible lesions did not see age-related effects,
while those that included them did, indicating that lesional MTR
dominates these age-related effects. The study of Fazekas et al. (2005)
showed an average 10% drop in mean MTR in white matter
hyperintensities (WMH). The MTR in these WMH was not related to
age, but as WMH become more prevalent with aging, this may explain
much of the age-related MTR decline seen when not speciﬁcally exclud-
ing them from analysis. Though large, this effect is smaller than the dif-
ference seen between NAWM and WMLs in our MS groups of about
20%. The age-related effects in normal controls demonstrated in the
two earlier studies underscore the requirement for an age-matched
group, which has allowed us to decouple age-related changes from
MS-related changes.
When comparing the control group to either MS group, strong
changes in mean MTRs and distributions in the NAGM and MTR
distributions in the NAWM were apparent. However, no signiﬁcant
differences were detected between the older and younger MS groups
in NAWM and NAGM, which accords with the only previous study of
aging and MTR in the MS population (Dehmeshki et al., 2003). There-
fore, while MS-related changes were noted, no age-related changes
were noted in the NAWM and NAGM.
This is the ﬁrst study which has attempted to examine age-related
changes within WMLs in MS. In WML, very strong differences in all
MTR metrics were seen between the young and older MS groups,
when controlled for clinical disease duration and despite ﬁnding similar
lesion loads in both groups. This implies that age inMS patients exerts a
direct negative effect upon CNS myelin integrity in MS WMLs that is
reﬂected in MTR.
MTR parameters have been widely quoted within MS literature. In
our study, average MTR values were within expected limits from previ-
ous studies; with average MTR of NAWM between 40 and 50 p.u. in a
normal brain (Horsﬁeld et al., 2003).We used semi-automated segmen-
tation techniqueswithmanual editing to delineate hyperintense lesions
on T2-weighted images and hypointense lesions on T1-weighted
images. This approach introduces a degree of inter-observer variability,
and we have attempted to reduce resultant error by using a second
experienced observer to corroborate lesion delineation. Automated
methods of segmenting gray and white matter have been previously
used in MS cohorts (Rovaris et al., 2003; Miller et al., 2002) with good
reproducibility.
As is common practice in histogram analysis, the MTR histograms
were normalized by each subject's tissue volume. However, the ROI
Fig. 1.Representative images from a subjectwith amoderate lesion load.MPRAGE (top row), T2-w FLAIR (second row), resultingMTRmap (third row), and ROI classiﬁcations overlaid on
the MPRAGE (bottom row). Yellow = NAWM, green = NAGM, blue =WML, red = GML.
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Fig. 2. Age at MRI, disease duration, relapses, and EDSS across groups. Age at time of MRI (a) and clinical disease duration (b) were dictated by study criteria and are therefore strongly
different (ages between younger and older groups) or well matched (all other comparisons). (c) No difference was found in number of relapses, but functional status as measured by
EDSS (d) differs signiﬁcantly between age groups.
646 R.D. Newbould et al. / NeuroImage: Clinical 4 (2014) 641–648volumes did differ in some comparisons. Even whenWMLs and NAWM
volumeswere summed to compare totalWM,MS subjects had less total
WM than controls, indicating an expected pathological volume loss.
Both MS groups had similar WM volumes. Interestingly, the young MS
subjects had similar GM volumes as the older controls; the older MS
subjects had less GM than either other group. Progressive GM loss is
well described in MS (Valsasina et al., 2005); our data raise theFig. 3.MTR histograms. NAWM shows a small leftward shift in both MS groups versus controls
older MS group shows much lower MTR values (c).possibility that this effect is more pronounced in older patients for a
given clinical disease duration, but this would require a formal compar-
ison including a young control group. As previously discussed, WML
volumes were similar in both MS groups.
Our study has a number of limitations. Due to the lack of an available
double inversion recovery (DIR) sequence (Wattjes et al., 2007) at the
beginning of this study, GMLs were quantiﬁed on a 3D T2w-FLAIR(a). NAGM has a more pronounced reduction in high MTR voxel counts (b). InWMLs, the
Fig. 4.Multivariate analysis. ROC curve showing the ability of the combination of the 4 var-
iables (EDSS, gray matter volume, T1 lesion volume, and mean MTR in WML) to distin-
guish young and old patients. AUC = 0.95, (95% CI = 0.88–1.00).
647R.D. Newbould et al. / NeuroImage: Clinical 4 (2014) 641–648volume, which has increased sensitivity to GMLs over a standard 2D
spin-echo based approach, but less sensitivity than the 3DDIR sequence
(Geurts et al., 2005). The delineation of GMLs was performed to ensure
that NAGMwasnormal appearing on both T1wand T2wvolumes. GMLs
were found in 12 of the 20 and 9 of the 18 subjects in the young and
older MS groups, respectively. If an additional 150% of the GMLs detect-
ed by 3D FLAIR would be classiﬁed as GML on DIR (Geurts et al., 2005),
these additional lesions would be mostly included in the NAGM. This
would represent 0.03% of the NAGM volume that was actually GML,
and unlikely to affect the interpretation of NAGM.
Our cohort study included 40MS subjects, similar to the cohort sizes
in the previously discussed studies, but only 13 control subjects. Both
our cohort sizes are smaller than other MTR studies in healthy subjects.
As noted above, the chosen cohort of rapidly-evolving MS subject was
expected to give a large effect size in MTR and lesion metrics between
healthy controls and subjects with MS, mitigating the limitations of a
small sample size. Indeed, the presence of benign or inactive forms of
MS in an unselected cohort would have decreased the sensitivity of
the experiment and hence the power to detect differences between
younger and older patients. This small sample size did produce mean-
ingful comparisons, though it was not large enough to interpret other
variables, such as the underlying age-related decline in ROI volumes.
Instead, these data must be interpreted using the results of other, larger
studies.
One possible confounder when examining GM with MTR is partial
volume effects between the GM and either or both cerebrospinal ﬂuid
(CSF) and WM. CSF has a low MTR, and therefore MTR would decrease
in nominally GM voxels which contain CSF, while the higher MTR in
WMwould increase the effect seen in nominally GM voxels which con-
tainWM. This study used high resolution (1mm isotropic) 3D datasets,
which will reduce the partial volume effect, and a high threshold (0.75)
for conﬁdence in the automated tissue classiﬁcation. GM atrophywould
increase the degree of partial volume effects, and therefore might give
spurious MTR in atrophied GM. However, MTR metrics were strongly
different between controls and young MS groups and NAGM volume
was similar, obviating these concerns.
We have attempted to match disease duration between groups by
deﬁning it as clinical disease duration based on the time elapsed since
clinical diagnosis of MS. This may not reﬂect the biological duration of
the disease, and there is a theoretical risk that older individuals have
had a longer subclinical duration before diagnosis. If the onset of symp-
toms could be reliably determined, it may be more closely linked to
biological onset, but to our knowledge no evidence exists that latencyfrom biological to clinical onset is longer in patients diagnosed with
MS at an older age.
This histogram-based study removed any anatomical location infor-
mation of the lesions, and treated the entire identiﬁed lesion as a uniform
area in the analysis. A more reﬁned approach, stratifying by brain region
or subdividing lesions into perilesional and deep lesional areasmay show
further effects; however, this was not done in this study.
To our knowledge, no previous study has compared MTR amongst
MS groups with age as the primary variable. While many studies have
examined the relationship of MTR values with clinical variables, we
have focused on the effects of age on the brain in MS. We suggest that
the decreased efﬁciency of myelination in aging, well described in non-
human primates (Bowley et al., 2010), and demyelinating injury inmul-
tiple sclerosis both contribute to the additional loss of myelin integrity
inWMLs revealed byMTR in the older patients in our study. This pathol-
ogy may be underpinned by a relative failure of remyelination in the
older patient; by analogy with animal studies where younger rats
remyelinate more quickly than in older rats (Shields et al., 1999), and
defective remyelination is abrogated by exposing older mice to the
circulation of younger animals (Ruckh Julia et al., 2012).
In support of our interpretation of the MTR results and of data from
experimental models, we ﬁnd that current age predicts functional
disability, as measured by EDSS, when patients are matched for clinical
disease duration and do not differ in other disease-relevant variables
such as number of preceding relapses and disease-modifying treat-
ments. This ﬁnding is in line with large natural history studies demon-
strating that older patients reach the progressive stage of the disease
more quickly than younger patients (Koch et al., 2007; Scalfari et al.,
2011). Therefore the reduction in MTR seen in the older age group
might be better explained as amodifying effect of aging on the outcome
of focal WM inﬂammatory insult in MS (which may include decreasing
efﬁciency of repair with aging) rather than by the severity of the primary
inﬂammatory insult, as exempliﬁed in animal studies (Shields et al.,
1999; Ruckh Julia et al., 2012).
In conclusion, the results of ourMTR analysis imply that aging in the
context of MS plays an important role in brain white matter integrity
and this is mirrored by differences in functional status between age
groups despite matching of the salient clinical variables. This work
corroborates earlier ﬁndings that indicate the crucial role that aging
plays in the clinical trajectory of MS, which is of relevance to the MS
community for the understanding and development of treatments for
progressive forms of the disease.
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